US20220000588A1 - High strength intraosseous implants - Google Patents
High strength intraosseous implants Download PDFInfo
- Publication number
- US20220000588A1 US20220000588A1 US17/476,182 US202117476182A US2022000588A1 US 20220000588 A1 US20220000588 A1 US 20220000588A1 US 202117476182 A US202117476182 A US 202117476182A US 2022000588 A1 US2022000588 A1 US 2022000588A1
- Authority
- US
- United States
- Prior art keywords
- intraosseous implant
- implant
- threaded
- nfm
- pcl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000007943 implant Substances 0.000 title claims abstract description 137
- 239000002121 nanofiber Substances 0.000 claims abstract description 40
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 31
- 239000000835 fiber Substances 0.000 claims abstract description 21
- 239000003102 growth factor Substances 0.000 claims abstract description 11
- 239000010936 titanium Substances 0.000 claims description 85
- 102000016359 Fibronectins Human genes 0.000 claims description 56
- 108010067306 Fibronectins Proteins 0.000 claims description 56
- 238000000576 coating method Methods 0.000 claims description 38
- 239000011248 coating agent Substances 0.000 claims description 35
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 claims description 33
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 claims description 33
- 102000008186 Collagen Human genes 0.000 claims description 22
- 108010035532 Collagen Proteins 0.000 claims description 22
- 229920001436 collagen Polymers 0.000 claims description 22
- CXCHEKCRJQRVNG-UHFFFAOYSA-N 2,2,2-trifluoroethanesulfonyl chloride Chemical compound FC(F)(F)CS(Cl)(=O)=O CXCHEKCRJQRVNG-UHFFFAOYSA-N 0.000 claims description 16
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 10
- 229910052719 titanium Inorganic materials 0.000 claims description 10
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 claims description 9
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 claims description 9
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 claims description 5
- 239000011159 matrix material Substances 0.000 claims description 5
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 2
- 230000000845 anti-microbial effect Effects 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 230000037431 insertion Effects 0.000 claims 3
- 238000003780 insertion Methods 0.000 claims 3
- 239000007787 solid Substances 0.000 claims 3
- 238000000034 method Methods 0.000 abstract description 36
- 230000008468 bone growth Effects 0.000 abstract description 21
- 208000015181 infectious disease Diseases 0.000 abstract description 7
- 230000004048 modification Effects 0.000 abstract description 6
- 238000012986 modification Methods 0.000 abstract description 6
- 230000007423 decrease Effects 0.000 abstract description 4
- 206010061218 Inflammation Diseases 0.000 abstract description 2
- 230000004054 inflammatory process Effects 0.000 abstract description 2
- 230000006444 vascular growth Effects 0.000 abstract description 2
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 abstract 2
- 101000762366 Homo sapiens Bone morphogenetic protein 2 Proteins 0.000 abstract 2
- 229920001610 polycaprolactone Polymers 0.000 description 38
- 239000004053 dental implant Substances 0.000 description 25
- 238000010883 osseointegration Methods 0.000 description 20
- 239000002105 nanoparticle Substances 0.000 description 19
- 230000000670 limiting effect Effects 0.000 description 15
- 230000000844 anti-bacterial effect Effects 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000000963 osteoblast Anatomy 0.000 description 10
- 238000011160 research Methods 0.000 description 10
- 238000010586 diagram Methods 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 7
- 238000001994 activation Methods 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000035876 healing Effects 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 5
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 5
- 229910000883 Ti6Al4V Inorganic materials 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000003915 cell function Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000002188 osteogenic effect Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 229910001069 Ti alloy Inorganic materials 0.000 description 4
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003833 cell viability Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 210000002744 extracellular matrix Anatomy 0.000 description 4
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000037408 Device failure Diseases 0.000 description 3
- 238000003794 Gram staining Methods 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- 208000008312 Tooth Loss Diseases 0.000 description 3
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000010072 bone remodeling Effects 0.000 description 3
- 230000021164 cell adhesion Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 230000003100 immobilizing effect Effects 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 230000000921 morphogenic effect Effects 0.000 description 3
- 230000000399 orthopedic effect Effects 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 230000002138 osteoinductive effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 238000007586 pull-out test Methods 0.000 description 3
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 3
- 230000036962 time dependent Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 229910045601 alloy Inorganic materials 0.000 description 2
- 239000000956 alloy Substances 0.000 description 2
- 230000010478 bone regeneration Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 230000005754 cellular signaling Effects 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000035800 maturation Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 231100000989 no adverse effect Toxicity 0.000 description 2
- 230000009818 osteogenic differentiation Effects 0.000 description 2
- 210000002379 periodontal ligament Anatomy 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000004381 surface treatment Methods 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 208000008822 Ankylosis Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 206010023198 Joint ankylosis Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 102100026632 Mimecan Human genes 0.000 description 1
- 101001055320 Myxine glutinosa Insulin-like growth factor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 101800002327 Osteoinductive factor Proteins 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 206010034133 Pathogen resistance Diseases 0.000 description 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000007227 biological adhesion Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000013043 cell viability test Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000001889 chemoattractive effect Effects 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001523 electrospinning Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000001815 facial effect Effects 0.000 description 1
- 238000007380 fibre production Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000010147 laser engraving Methods 0.000 description 1
- 238000010329 laser etching Methods 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000933 neural crest Anatomy 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 210000002997 osteoclast Anatomy 0.000 description 1
- 230000000278 osteoconductive effect Effects 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 208000028169 periodontal disease Diseases 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 229920005594 polymer fiber Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011555 rabbit model Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000006557 surface reaction Methods 0.000 description 1
- 230000003746 surface roughness Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0003—Not used, see subgroups
- A61C8/0004—Consolidating natural teeth
- A61C8/0006—Periodontal tissue or bone regeneration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C13/00—Dental prostheses; Making same
- A61C13/0003—Making bridge-work, inlays, implants or the like
- A61C13/0006—Production methods
- A61C13/0018—Production methods using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
- A61C8/0013—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy with a surface layer, coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0012—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy
- A61C8/0016—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the material or composition, e.g. ceramics, surface layer, metal alloy polymeric material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61C—DENTISTRY; APPARATUS OR METHODS FOR ORAL OR DENTAL HYGIENE
- A61C8/00—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools
- A61C8/0018—Means to be fixed to the jaw-bone for consolidating natural teeth or for fixing dental prostheses thereon; Dental implants; Implanting tools characterised by the shape
- A61C8/0022—Self-screwing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
- A61K6/891—Compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/80—Preparations for artificial teeth, for filling teeth or for capping teeth
- A61K6/884—Preparations for artificial teeth, for filling teeth or for capping teeth comprising natural or synthetic resins
- A61K6/898—Polysaccharides
Definitions
- the present invention generally relates to the field of polymer fiber production and biomedical applications thereof. More specifically, the invention relates to improving performance of metallic dental implants by attachment of augmented electrospun fibers exhibiting micron to nano size diameters.
- Electrospun Nanofibers have numerous biomedical applications.
- Co-pending application Ser. No. 14/734,147 and U.S. Pat. No. 9,359,694 by the present Applicant discloses a method and apparatus for controlled deposition of branched electrospun fiber on biomedical implants and material, the disclosures of which are incorporated herein by reference in the entirety.
- Research has shown that micron to nano size fibers may be fused with biomedical implants for improving the mechanical and biological adhesion of titanium implants with the host tissue.
- Nano size fibers have been found to be excellent carriers of drugs for improving bone growth. If applied as a coating around the implant, improved bone growth may reduce the implant loosening problem.
- Tooth loss is a significant public health issue, increasing the risk of a wide range of conditions such as malnutrition due to lack of proper masticatory function and clinical depression due to the change in facial appearance. Tooth loss is primarily caused by periodontal disease, dental caries, or trauma. The prevalence of all risk factors of tooth loss increases with age and is thus projected to increase with the growth of the aging population across the world. In the United States, the population over 65 years of age is projected to reach 83.7 million by 2050. Though the success rate of dental implant surgery is high, the failure of implants due to poor osseointegration has been reported.
- Threaded endosseous devices with a cylindrical or tapered shape are the most widely used type of dental implant.
- Endosseous dental implants are surgically inserted into the jawbone.
- Osseointegration refers to bone grown right up to the implant surface without interposed soft tissue layer.
- micro-motions occur at the implant surface that lead to osteoclast-driven resorption of bone around the implant, contributing to further implant loosening and eventual implant failure. Delayed bone healing leads to potential failure of the dental implant.
- implant loosening due to poor osseointegration and healing leads to economic burdens.
- implant length and diameter are important in determining the stability of the implant and the maximum load that can be placed on the implant. Generally, at least 7-9 mm of bone depth is required for implant placement, with implant width varying from 3-7 mm in diameter. These dimensions often act as limiting factors when insufficient bone is present for implant placement. Thus, there is a need for stronger implants with higher functional loads and osseointegration.
- the present invention is directed to increasing success rate of implant surgeries and decreasing integration time independent of the physical properties of implants.
- the present invention is unique in that it provides a method of incorporating a system of bioaugmentation of metal implants by introducing a PCL ENF carrying a recombinant growth factor, such as BMP2 (Bone Morphogenetic Protein 2) or PDGF (Platelet Derived Growth Factor).
- BMP2 Bisphogenetic Protein 2
- PDGF Platinum Derived Growth Factor
- These growth factors have been extensively shown to activate neural crest-derived bone stem cells to aid in differentiation, regeneration, and maturation of bone.
- the properties of the fiber allow for binding to an antibiotic agent, such as silver nanoparticles (Ag NP), thus making the implant itself to exhibit antiomicrobial properties, decreasing the risk of implant failure due to infection.
- an antibiotic agent such as silver nanoparticles (Ag NP)
- the present invention enables modification of an intraosseous implant device that is not only biologically non-inert, but can (1) stimulate bone and vascular growth (2) decrease localized inflammation, and (3) fight local infections.
- the method of the present invention provides a fiber with at least any of the following modifications:
- Nanofiber with PDGF 1.
- nanofiber can be modified with many growth factors that have been shown to play a role in regulation of physiological bone remodeling to improve bone growth and maturation. These may include, for example, IGFs, TGF- ⁇ , FGFs, EGF, and WNTs, as well as BMP and PDGF.
- growth factors include, for example, IGFs, TGF- ⁇ , FGFs, EGF, and WNTs, as well as BMP and PDGF.
- MPC mesenchymal progenitor cells
- the effect of rhBMP-2, rxBMP-4, and rhPDGF-bb as chemoattractive proteins for primary human MPC has been shown to be highly significant.
- BMP and PDGF are the most commonly ones employed.
- Titanium-based implants have been widely used in orthopedics and orthodontic surgeries because of their strong mechanical, chemical and biological properties.
- a set of steps e.g. grooving and oxidizing
- a nanofiber matrix composed of collagen (CG) and poly- ⁇ -caprolactone (PCL) electrospun nanofibers
- CG-PCL NFM-coated Ti over non-coated Ti not previously known was observed in our experiments.
- the advantage of functional coating treatment on an implant is that it is simple, indirect, scalable, inexpensive, and supplementary to other surface treatment techniques. Such treatment can be applied on an implant surface without affecting other implant factors, such as mechanical, medication (e.g. drugs, irradiation), and patient (e.g. age, osteopenia) factors.
- the biological properties of a functional coating can be further improved by adding growth factors, proteins, and other molecules to create a truly osteoinductive platform at the implant/bone interface.
- the present invention provides an improved intraosseous implant device capable of decreasing the time periods for osseointegration and preventing post-operative local infections.
- Titanium (Ti) alloy is most widely used as a dental implant material.
- FN fibronectin
- Our studies show that microgrooving on cylindrical Ti implants and subsequent coating of the grooves with collagen-poly- ⁇ -caprolactone nanofiber matrix (CG-PCL NFM) significantly improves the biocompatibility, mechanical stability and osseointegration of Ti.
- CG-PCL NFM collagen-poly- ⁇ -caprolactone nanofiber matrix
- a laser pulse can create microgrooves on the surface of regular- and irregular-shaped implants.
- a literature search has revealed no reported research directed to the controlled fabrication of microgrooves on a complex-shaped implant surface, such as a dental implant ( FIG. 1 ).
- the effect of coating the laser-induced microgrooves with bone morphogenetic protein-2 (BMP2)- and silver (Ag) nanoparticle (NP)-immobilized PCL NFM on a dental implant has not been reported. Attachment of BMP2 and Ag NP onto Ti dental implant is sought via FN and CG immobilized PCL NFM, respectively.
- the above mentioned surface treatments on a dental implant may have the potential to improve the implant osseointegration, reducing both healing time, and risk of infection.
- the present invention provides methods for attachment of osseointegration-promoting and anti-bacterial biomolecules on a dental implant using laser-induced microgrooves and PCL NFM.
- Immobilization of BMP2 with PCL NFM referred as BMP2-PCL
- subsequent coating of a laser-microgrooved titanium implant by BMP2-PCL may lead to greater in vitro and in vivo osteogenic functions in comparison to the non-treated implants due to higher biological compatibility of the BMP2-PCL-coated implant.
- Ag-PCL PCL NFM
- Immobilization of Ag NP with PCL NFM referred as Ag-PCL
- subsequent coating of a laser-microgrooved titanium implant by Ag-PCL may lead to lower risk of bacterial development in comparison to the non-treated implants due to higher anti-bacterial resistance of the Ag-PCL-coated implant.
- the present invention provides methods for fabrication of the control microgrooves at the interspace between two threads of a dental implant. Fabrication of such grooves can have medical benefits, since grooves on implants induce a higher amount of implant-bone contact area and osteoblast cell function in comparison to implants without grooves.
- the implant body is strongly torqued and drilled into hard bone.
- the microgrooves protect the functional NFM coating from these applied loads.
- the NFM coating can serve as a reservoir at the microgrooves on dental implant surfaces for controlled release of bone growth factor and anti-bacterial molecules for reducing infection and promoting osteogenesis.
- Laser pulse is a method used to produce high precision, high roughness, and uniform microgroove topography on a dental implant along the threaded and non-threaded sections.
- the present invention provides methods for attachment of the functional PCL NFM coating on a dental implant of any size or shape.
- Tresyl chloride a chemical activation technique, can be used to attach FN on the dental implant surface directly.
- the bone growth signaling factors and collagen binding domain of FN can be utilized to attach bone growth factors (BMP2) and anti-bacterial molecules (Ag NP) immobilized PCL NFM with Ti.
- BMP2 bone growth factors
- Ag NP anti-bacterial molecules
- the present invention provides methods for a direct immobilization technique using bone growth factors (BMP2) and anti-bacterial molecules (Ag NP) on a human dental implant surface via PCL NFM.
- BMP2 bone growth factors
- Ag NP anti-bacterial molecules
- Such treatment methods can be applied not only to improve dental implant-to-bone interface, but also to anchor many other orthopedic biomaterials.
- Nanofiber can be applied on the surface of an implant in several ways. First, a spiral micro-notching can be applied on the implant in the same direction as the threads, with the nanofibers embedded into the notches. Second, the entire surface of the implant may be coated with a mesh of nanofibers. Third, it can be a combination of both embedding and notching.
- FIG. 1 is a non-limiting diagram showing microgrooves and nanofiber-assisted drug delivery on dental implant as provided by the present invention.
- FIG. 2 is a non-limiting diagram showing the method of the present invention providing protein immobilization on Ti using nanofiber matrix as a functional coating.
- FIG. 3 is a non-limiting diagram showing F1s, S2p, N1s and O1s spectra of the Ti, Tresyl/Ti, and FN/Ti surface by a XPS analysis.
- FIG. 4 is a non-limiting diagram showing precision microgrooves on the flat surface of a Ti rod formed by the method of the present invention.
- FIG. 5 is a non-limiting diagram showing schematic representation of the processes for preparing an in vivo dental implant.
- FIG. 6 a is a non-limiting diagram showing a 3 mm diameter screw coated with 18 layers of PCL NFM.
- FIG. 6 b is a non-limiting diagram showing twisting of an NFM coated screw in to a pre-drilled hole (2.6 mm diameter) on a clear acrylic shows homogenous distribution of fiber along screw/acrylic interface.
- FIG. 7 a is a non-limiting image showing individual immobilization of CG and FN on PCL NFM.
- FIG. 7 b is a non-limiting graph showing that the individual immobilization of CG and FN on PCL NFM has no adverse effect on osteoblast cells adhesion and proliferation of PCL NFM, and significant increase of cell adhesion observed for FN-PCL-NFM when compared to PCL NFM (p ⁇ 0.05).
- FIG. 8 a is a non-limiting graph showing a gradual increase of release of BMP2 for 28 days was observed for FN-Hep-BMP2/PCL samples.
- FIG. 8 b is a non-limiting image showing cell divisions after 48 hours of cell culture on FN-BMP2-PCL samples.
- FIG. 9 a is a non-limiting image showing PCL samples after Gram staining.
- FIG. 9 b is a non-limiting image showing CG-Ag-PCL samples after Gram staining.
- FIG. 10 is a non-limiting diagram presenting the test results of time-dependent bone growth around the CG-PCL NFM-coated Ti implant and related in vivo pull-out tests to demonstrate mechanical stability of microgrooved-Ti.
- the present invention 10 provides coating methods described above to dental implants with the goal of improving the osseointegration of implants.
- Laser-induced microgrooves 11 were shown in our research to significantly influence the surface morphology, contact angle, surface roughness, and chemical composition of Ti that can influence the attachment of fibronectin on implants.
- a set of continuous microgrooves 11 with 50 ⁇ m width, 5 ⁇ m depth, and 150 ⁇ m spacing between grooves are engraved at the root of the threads ( ⁇ 0.5 mm) on a Di 12 using a laser system (e.g., a Galvo FP fiber marking) to produce a laser-microgrooved Di 13 .
- a rotary stage of the laser system (not shown) is oriented according to the helix angle of the implant threads to produce the laser microgrooves 11 at the root 14 of the threads 18 .
- FN is attach on the laser-engraved implant 12 surface by tresyl chloride method 21 , and coats the FN-immobilized implant surface 22 with BMP2- and Ag-immobilized PCL NFM as shown 23 .
- Basic terminal hydroxyl groups of a pure titanium surface 22 react with tresyl chloride, which allows for further coupling with fibronectin (FN).
- FN fibronectin
- Tresyl/Ti the top surface of a polished Ti-6Al-4V sample was treated with 2,2,2-Trifluoroethanesulfonyl chloride at 36° C. for 48 hours, then washed with water, water-acetone (50:50), and acetone. Samples were then dried and stored in a desiccator.
- FN/Ti a Tresyl/Ti sample was treated for 24 hours at 37° C. with human plasma fibronectin diluted in phosphate-buffered saline (PBS) solution to a concentration of 0.1 mg/mL.
- X-ray photoelectron spectroscopy (XPS) analysis was conducted on all samples to determine the chemical state of Ti. The binding energy for each spectrum was calibrated against the C1s peak at 284.8 eV.
- XPS analysis found the presence of an amide group for FN/Ti, which confirms the surface activation by tresyl chloride and then direct coupling of FN with Ti.
- the N1s peak derived from the amide bond of immobilized fibronectin, was detected around the binding energy of 400 eV for only FN/Ti samples. Therefore, this study suggested that direct attachment of FN is possible on a tresylated Ti alloy surface.
- Our proof of concept for the potential application of the treatment protocols on a Di led to the following: an ideal functional coating for a Di must reabsorb with time to allow and encourage new bone formation while maintaining its osteoconductive properties in vivo.
- the present invention provides laser engraving 41 to support attachment of FN on a dental implant ( FIG. 1-12 ) and then coating the implant with BMP2 and Ag NP-immobilized PCL NFM.
- a laser pulse can be applied on the polished surfaces of Ti to create linear and continuous microgrooves on Ti implants.
- a laser capable of producing precision microgrooves ( FIG. 1-11 ) on at least the flat surface of a Ti rod 42 can be used for this purpose.
- a Galvo FP fiber marking laser equipped with software for engraving a set of microgrooves (10 ⁇ m width, 5 ⁇ m depth, and 50 ⁇ m spacing between grooves) on Ti.
- each groove of this size can accommodate at least 18 layers of nanofiber (average fiber diameter ⁇ 300 nanometers).
- we use 18 layers of PCL NFM because our research shows that the porosity of a PCL NFM membrane comprising 18 layers of fibers is adequate for cells to migrate through the membrane.
- FN can be attached on laser engraved Ti implants (lgTi), where immobilization of FN with Ti is accomplished by the tresyl chloride method as provided by the present invention.
- aligned unidirectional PCL NFM can be collected using the methods disclosed in U.S. Pat. No. 9,809,906 by the present Applicant and illustrated in FIG. 5 .
- the laser-grooved surface of lgTi is activated by tresyl chloride and then 18 layers of PCL NFM is deposited along the direction of the thread (clockwise) by rotating the tresylated Di 18 times until the implant collects 18 layers of fibers.
- the reason for adapting this coating method on a Di surface is due to fact that such a method should be able to maintain nanofibers along the Di/bone interface.
- FN, FN-Hep-BMP2 and CG-Ag complexes are gently splashed on the PCL coated Di samples to prepare FN-PCL/Di, FN-BMP-PCL/Di and CG-Ag-PCL/Di Di, respectively. All implants are prepared under sterile conditions and kept for 30 minutes in a portable ultraviolet sterilizer before surgery.
- FIGS. 6 a and 6 b in a method validation test we coated a M3 ⁇ 0.5 screw by PCL NFM using the method of the present invention ( FIG. 5 ). We torqued the fiber-coated screw in to a pre-drilled hole (2.6 mm) on clear acrylic ( FIG. 6 b ). We observed homogeneously-distributed fiber along the interface between the screw and the acrylic ( FIG. 6 b ).
- BMP2 Bone Morphogenic Protein-2
- Bone morphogenic proteins play important roles in in osteoblast and chondrocyte differentiation. Research shows that surface functionalization of Ti with BMP2 improves the osteoblast activities of Ti. Among BMP family members, BMP2 is a potent osteoinductive factor that plays key role during bone formation. Fibronectin (FN) is a multifunctional protein most abundantly found in the extracellular matrix (ECM) under dynamic remodeling conditions such as bone healing and development. Research shows that tethering of FN onto Ti effectively enhanced the bone regeneration around implants. Our preliminary studies show that FN-immobilized PCL NFM (referred as FN-PCL) has higher biocompatibility with osteoblast cells in comparison to PCL.
- FN-PCL FN-immobilized PCL NFM
- FN contains binding domains for many bone growth signaling factors, including BMP2 and transforming growth factor-beta (TGF- ⁇ ).
- BMP2 transforming growth factor-beta
- TGF- ⁇ transforming growth factor-beta
- Ag NP inhibits bacterial growth, while retaining/promoting osteoblast viability.
- common antibacterial nanoparticles Ag, CuO, ZnO
- Ag NP shows the minimum toxicity to environmentally relevant test organisms and mammalian cells in vitro and in vivo. Since Ag NP dissolves in CG, it can be immobilized with CG-PCL NFM. Our in vivo and in vitro studies show that CG-PCL NFM coating enhanced biological functions of Ti.
- Fibronectin contains several active sites, known as the heparin-binding domains, collagen-binding domain, fibrin-binding domain, and cell-binding domain, that serve as platforms for cell anchorage.
- the goal of this preliminary study was to evaluate the effect of immobilization of collagen and plasma fibronectin with PCL NFM on the cellular functions of PCL NFM.
- the results show that the individual immobilization of CG and FN on PCL NFM has no adverse effect on osteoblast cells adhesion and proliferation of PCL NFM, although a significant increase of cell adhesion was observed for FN-PCL-NFM when compared to PCL NFM (p ⁇ 0.05).
- BMP2 Human Bone Morphogenic Protein-2
- FN Fibronectin
- the PCL NFM can be modified with heparin (Hep) and further immobilized with BMP2.
- the modified fibers showed the potential to effectively induce osteogenic differentiation of periodontal ligament cells. Since FN contains heparin-binding domains, PCL fibers can be modified with FN-Hep-BMP2 complex.
- the purpose of this preliminary study was threefold: (1) to immobilize BMP2 on PCL NFM using only FN-BMP2 and FN-Hep-BMP2 complexes, (2) to determine the amount of BMP2 release from the immobilized BMP2-PCL NFM, and (3) to compare the cell viability of BMP2-immobilized PCL NFMs with respect to PCL NFM (control).
- Immobilized BMP2 was released from the PCL NFMs in a sustained manner for 28 days, although the rates of release of BMP2 from FN-BMP2/PCL and FN-Hep-BMP2/PCL were different.
- a gradual increase of release of BMP2 for 28 days was observed for FN-Hep-BMP2/PCL samples ( FIG. 8 a ).
- Rapid release of BMP2 for first 4 days, then gradual decline of release of BMP2 with time was observed for FN-BMP2/PCL samples.
- Cells displayed a well-extended morphology on all the BMP2-treated groups, when they were compared with the control group ( 8 a ).
- 8 b depicts a representative image showing cell divisions after 48 hours of cell culture on FN-BMP2-PCL samples.
- blue color shows the attachment of cells on NFM.
- FN-Hep-BMP2-PCL samples After culturing the cells for 72 hours compared to control and FN-BMP2-PCL.
- Both release and cell viability tests suggested an advantage of FN-Hep-BMP2 over FN-BMP2 complex for the immobilization of BMP2 with PCL NFM.
- FN-Hep-BMP2 immobilized PCL NFM has the potential to induce osteogenic differentiation of osteoblast cells on a Ti implant surface, which is not yet known.
- the effect of the treatment of Ti with FN by tresyl chloride method and then coating by FN-Hep-BMP2/PCL on the osteogenic functions needs to be investigated.
- Silver nanoparticles show promising anti-bacterial properties with biocompatibility and minimal toxicity.
- Ag NP-loaded collagen was immobilized with polymeric film to inhibit bacterial growth while promoting osteoblast cell viability.
- the anti-bacterial activities of PCL NFM can be improved by immobilizing Ag NP-loaded CG with PCL NFM.
- the purpose of this preliminary study was to examine the effect of immobilization of Ag NP-loaded CG on the anti-bacterial properties of PCL NFM.
- the SEM and XRD analysis before and after 2 days of bacterial culture confirmed the presence of Ag with PCL.
- FIG. 9 shows PCL samples after Gram staining: (a) PCL and (b) CG-Ag-PCL. S. aureus that take up the Gram stain were present in PCL, as observed in the image by circular black shapes (pointed by arrows), while CG-Ag-PCL without S. aureus , did not stain and appears with a gray color.
- One reason for this might arise from an increased carrying capacity of Ag NP-loaded collagen by the nanofiber disc due to its unique surface-to-volume ratio.
Landscapes
- Health & Medical Sciences (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dentistry (AREA)
- Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ceramic Engineering (AREA)
- Plastic & Reconstructive Surgery (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Manufacturing & Machinery (AREA)
- Biomedical Technology (AREA)
- Developmental Biology & Embryology (AREA)
- Materials For Medical Uses (AREA)
- Prostheses (AREA)
Abstract
The present invention enables modification of an intraosseous implant device that is not only biologically non-inert, but can stimulate bone and vascular growth; decrease localized inflammation; and fight local infections. The method of the present invention provides a fiber with any of the following modifications: (1) Nanofiber with PDGF, (2) Nanofiber with PDGF+BMP2, and (3) Nanofiber with BMP2 and Ag. Nanofiber can be modified with other growth factors that have been shown to improve bone growth and maturation—BMP and PDGF being the most common. Nanofiber can be applied on the surface of the implant in several ways. First, a spiral micro-notching can be applied on the implant in the same direction as the threads with the nanofibers embedded into the notches. Second, the entire surface of the implant may be coated with a mesh of nanofibers. Third, it can be a combination of both embedding and notching.
Description
- This application is a continuation of U.S. patent application Ser. No. 17/374,700 filed Jul. 13, 2021 by the University of Central Oklahoma entitled “High strength intraosseous implants” which is a continuation of U.S. patent application Ser. No. 16/286,005 filed Feb. 26, 2019 by the University of Central Oklahoma (Applicant), and now U.S. Pat. No. 11,058,521 B2, entitled “Method and apparatus for improving osseointegration, functional load, and overall strength of intraosseous implants” which application is a continuation-in-part and claims benefit of U.S. patent application Ser. No. 16/248,122 filed Jan. 15, 2019 by the University of Central Oklahoma (Applicant), entitled “Nanofiber coating to improve biological and mechanical performance of joint prosthesis” the entire disclosure of which is incorporated herein by reference in its entirety for all purposes. This application claims the benefit of U.S. Provisional Patent Application No. 62/634,993 filed on Feb. 26, 2018 in the name of Vagan Tapaltsyan and Morshed Khandaker, which is expressly incorporated herein by reference in its entirety.
- This invention was made with government support under Grant Number 5P20GM103447 awarded by the National Institutes of Health. The government has certain rights in the invention.
- The present invention generally relates to the field of polymer fiber production and biomedical applications thereof. More specifically, the invention relates to improving performance of metallic dental implants by attachment of augmented electrospun fibers exhibiting micron to nano size diameters.
- Polycaprolecton (PCL) Electrospun Nanofibers (ENF) have numerous biomedical applications. Co-pending application Ser. No. 14/734,147 and U.S. Pat. No. 9,359,694 by the present Applicant discloses a method and apparatus for controlled deposition of branched electrospun fiber on biomedical implants and material, the disclosures of which are incorporated herein by reference in the entirety. Research has shown that micron to nano size fibers may be fused with biomedical implants for improving the mechanical and biological adhesion of titanium implants with the host tissue. Nano size fibers have been found to be excellent carriers of drugs for improving bone growth. If applied as a coating around the implant, improved bone growth may reduce the implant loosening problem. U.S. Pat. Nos. 10,206,780 and 9,809,906 by the present Applicant disclose methods to achieve adhesion of functional nanofiber coatings on a biomedical implant surface to increase the osteoinductive properties, and thereby to improve osseointegration of an implant, the disclosures of which are incorporated herein by reference in the entirety. The method uses PCL ENF fiber applied as a coating material, forming an extracellular matrix on an implant to improve ENF fiber adhesion with an implant surface, enabling use at physiological load bearing conditions. The method supports attachment of ENF fibers to an implant surface for both regular and irregular shape implants and enables drug delivery to promote bone growth.
- The loss of teeth is a significant public health issue, increasing the risk of a wide range of conditions such as malnutrition due to lack of proper masticatory function and clinical depression due to the change in facial appearance. Tooth loss is primarily caused by periodontal disease, dental caries, or trauma. The prevalence of all risk factors of tooth loss increases with age and is thus projected to increase with the growth of the aging population across the world. In the United States, the population over 65 years of age is projected to reach 83.7 million by 2050. Though the success rate of dental implant surgery is high, the failure of implants due to poor osseointegration has been reported.
- Threaded endosseous devices with a cylindrical or tapered shape are the most widely used type of dental implant. Endosseous dental implants are surgically inserted into the jawbone. Osseointegration refers to bone grown right up to the implant surface without interposed soft tissue layer. Alveolar bone osseointegrates with the implant without development of a periodontal ligament. In cases of decreased primary stability of the implant in bone, micro-motions occur at the implant surface that lead to osteoclast-driven resorption of bone around the implant, contributing to further implant loosening and eventual implant failure. Delayed bone healing leads to potential failure of the dental implant. Along with physical pain and suffering, implant loosening due to poor osseointegration and healing leads to economic burdens.
- Healing, surgical success, and complete osseointegration are regarded as the most important characteristics of dental (and, to large extent, orthopedic) intraosseous implants. Currently, efforts to improve implant success and osseointegration rates focus on the mechanical aspects of implants, such as the type of alloy, taper, screw thread design, metal finish (acid and laser etching, polishing), etc. All intraosseous devices of the above classes are classified as biologically inert implants, as implant integration occurs through a process of bone remodeling, resulting in total ankylosis. Another approach to improve osseointegration is the direct attachment of osteoinductive nanoscale topographies on endosseous dental implant surfaces. The main concern related to coating nanoscale materials onto an implant surface is the risk of coating detachment and toxicity of related debris. Further, implant length and diameter are important in determining the stability of the implant and the maximum load that can be placed on the implant. Generally, at least 7-9 mm of bone depth is required for implant placement, with implant width varying from 3-7 mm in diameter. These dimensions often act as limiting factors when insufficient bone is present for implant placement. Thus, there is a need for stronger implants with higher functional loads and osseointegration.
- The present invention is directed to increasing success rate of implant surgeries and decreasing integration time independent of the physical properties of implants. The present invention is unique in that it provides a method of incorporating a system of bioaugmentation of metal implants by introducing a PCL ENF carrying a recombinant growth factor, such as BMP2 (Bone Morphogenetic Protein 2) or PDGF (Platelet Derived Growth Factor). These growth factors have been extensively shown to activate neural crest-derived bone stem cells to aid in differentiation, regeneration, and maturation of bone. Moreover, the properties of the fiber allow for binding to an antibiotic agent, such as silver nanoparticles (Ag NP), thus making the implant itself to exhibit antiomicrobial properties, decreasing the risk of implant failure due to infection.
- The aforementioned innovations can result in higher stability and retention of intraosseous implants. Thus, while current dental bio-inert implants require 7-9 mm of bone depth, addition of modified PCL ENFs may decrease that requirement due to growth factor-driven improved bone quality and improved osseointegration. Also, current bio-inert implants require 4-6 months for complete osseointegration, while PCL ENF modification may significantly reduce the osseointegration time and speed up recovery. Finally, the present invention may allow for a wider range of acceptable surgical sites for implant placement due to the ENF's ability to stimulate new bone growth.
- The present invention enables modification of an intraosseous implant device that is not only biologically non-inert, but can (1) stimulate bone and vascular growth (2) decrease localized inflammation, and (3) fight local infections. The method of the present invention provides a fiber with at least any of the following modifications:
- 1. Nanofiber with PDGF
- 2. Nanofiber with PDGF+BMP2
- 3. Nanofiber with BMP2 and Ag
- Further, nanofiber can be modified with many growth factors that have been shown to play a role in regulation of physiological bone remodeling to improve bone growth and maturation. These may include, for example, IGFs, TGF-β, FGFs, EGF, and WNTs, as well as BMP and PDGF. Bone development, remodeling, and repair requires attraction of mesenchymal progenitor cells (MPC) and differentiation of MPC into osteoblasts. The effect of rhBMP-2, rxBMP-4, and rhPDGF-bb as chemoattractive proteins for primary human MPC has been shown to be highly significant. Thus, BMP and PDGF are the most commonly ones employed.
- Titanium-based implants have been widely used in orthopedics and orthodontic surgeries because of their strong mechanical, chemical and biological properties. We have tested a set of steps (e.g. grooving and oxidizing) by which a nanofiber matrix (NFM), composed of collagen (CG) and poly-ε-caprolactone (PCL) electrospun nanofibers, can be coated on a Ti implant without subsequent detachment. A significantly improved osseointegration of CG-PCL NFM-coated Ti over non-coated Ti not previously known was observed in our experiments. The advantage of functional coating treatment on an implant is that it is simple, indirect, scalable, inexpensive, and supplementary to other surface treatment techniques. Such treatment can be applied on an implant surface without affecting other implant factors, such as mechanical, medication (e.g. drugs, irradiation), and patient (e.g. age, osteopenia) factors. The biological properties of a functional coating can be further improved by adding growth factors, proteins, and other molecules to create a truly osteoinductive platform at the implant/bone interface.
- In one major aspect the present invention provides an improved intraosseous implant device capable of decreasing the time periods for osseointegration and preventing post-operative local infections. Titanium (Ti) alloy is most widely used as a dental implant material. We have developed a novel method of coating cylindrical Ti implants with nanofiber mesh by microgrooving. We have also immobilized fibronectin (FN), a glycoprotein of the extracellular matrix, on a Ti alloy (Ti-6Al-4V) by tresyl chloride-activation method. Our studies show that microgrooving on cylindrical Ti implants and subsequent coating of the grooves with collagen-poly-ε-caprolactone nanofiber matrix (CG-PCL NFM) significantly improves the biocompatibility, mechanical stability and osseointegration of Ti. A laser pulse can create microgrooves on the surface of regular- and irregular-shaped implants. A literature search has revealed no reported research directed to the controlled fabrication of microgrooves on a complex-shaped implant surface, such as a dental implant (
FIG. 1 ). The effect of coating the laser-induced microgrooves with bone morphogenetic protein-2 (BMP2)- and silver (Ag) nanoparticle (NP)-immobilized PCL NFM on a dental implant has not been reported. Attachment of BMP2 and Ag NP onto Ti dental implant is sought via FN and CG immobilized PCL NFM, respectively. The above mentioned surface treatments on a dental implant may have the potential to improve the implant osseointegration, reducing both healing time, and risk of infection. - In another major aspect the present invention provides methods for attachment of osseointegration-promoting and anti-bacterial biomolecules on a dental implant using laser-induced microgrooves and PCL NFM. Immobilization of BMP2 with PCL NFM (referred as BMP2-PCL) and subsequent coating of a laser-microgrooved titanium implant by BMP2-PCL may lead to greater in vitro and in vivo osteogenic functions in comparison to the non-treated implants due to higher biological compatibility of the BMP2-PCL-coated implant. Immobilization of Ag NP with PCL NFM (referred as Ag-PCL) and subsequent coating of a laser-microgrooved titanium implant by Ag-PCL may lead to lower risk of bacterial development in comparison to the non-treated implants due to higher anti-bacterial resistance of the Ag-PCL-coated implant.
- In another major aspect the present invention provides methods for fabrication of the control microgrooves at the interspace between two threads of a dental implant. Fabrication of such grooves can have medical benefits, since grooves on implants induce a higher amount of implant-bone contact area and osteoblast cell function in comparison to implants without grooves. During implantation, the implant body is strongly torqued and drilled into hard bone. The microgrooves protect the functional NFM coating from these applied loads. The NFM coating can serve as a reservoir at the microgrooves on dental implant surfaces for controlled release of bone growth factor and anti-bacterial molecules for reducing infection and promoting osteogenesis. Laser pulse is a method used to produce high precision, high roughness, and uniform microgroove topography on a dental implant along the threaded and non-threaded sections.
- In another major aspect the present invention provides methods for attachment of the functional PCL NFM coating on a dental implant of any size or shape. Tresyl chloride, a chemical activation technique, can be used to attach FN on the dental implant surface directly. The bone growth signaling factors and collagen binding domain of FN can be utilized to attach bone growth factors (BMP2) and anti-bacterial molecules (Ag NP) immobilized PCL NFM with Ti. The combined effect of FN immobilization on laser-microgrooved Ti and coating those grooves by PCL NFM provides a novel technique to attach the functional PCL NFM coating on any Ti implant.
- In another major aspect the present invention provides methods for a direct immobilization technique using bone growth factors (BMP2) and anti-bacterial molecules (Ag NP) on a human dental implant surface via PCL NFM. A potential opportunity for the advancement of in-vivo tissue-to-implant osseointegration, faster healing times, and reduction of infection of a dental implant are possible from these inventions. Such treatment methods can be applied not only to improve dental implant-to-bone interface, but also to anchor many other orthopedic biomaterials.
- Nanofiber can be applied on the surface of an implant in several ways. First, a spiral micro-notching can be applied on the implant in the same direction as the threads, with the nanofibers embedded into the notches. Second, the entire surface of the implant may be coated with a mesh of nanofibers. Third, it can be a combination of both embedding and notching.
-
FIG. 1 is a non-limiting diagram showing microgrooves and nanofiber-assisted drug delivery on dental implant as provided by the present invention. -
FIG. 2 is a non-limiting diagram showing the method of the present invention providing protein immobilization on Ti using nanofiber matrix as a functional coating. -
FIG. 3 is a non-limiting diagram showing F1s, S2p, N1s and O1s spectra of the Ti, Tresyl/Ti, and FN/Ti surface by a XPS analysis. -
FIG. 4 is a non-limiting diagram showing precision microgrooves on the flat surface of a Ti rod formed by the method of the present invention. -
FIG. 5 is a non-limiting diagram showing schematic representation of the processes for preparing an in vivo dental implant. -
FIG. 6a is a non-limiting diagram showing a 3 mm diameter screw coated with 18 layers of PCL NFM. -
FIG. 6b is a non-limiting diagram showing twisting of an NFM coated screw in to a pre-drilled hole (2.6 mm diameter) on a clear acrylic shows homogenous distribution of fiber along screw/acrylic interface. -
FIG. 7a is a non-limiting image showing individual immobilization of CG and FN on PCL NFM. -
FIG. 7b is a non-limiting graph showing that the individual immobilization of CG and FN on PCL NFM has no adverse effect on osteoblast cells adhesion and proliferation of PCL NFM, and significant increase of cell adhesion observed for FN-PCL-NFM when compared to PCL NFM (p<0.05). -
FIG. 8a is a non-limiting graph showing a gradual increase of release of BMP2 for 28 days was observed for FN-Hep-BMP2/PCL samples. -
FIG. 8b is a non-limiting image showing cell divisions after 48 hours of cell culture on FN-BMP2-PCL samples. -
FIG. 9a is a non-limiting image showing PCL samples after Gram staining. -
FIG. 9b is a non-limiting image showing CG-Ag-PCL samples after Gram staining. -
FIG. 10 is a non-limiting diagram presenting the test results of time-dependent bone growth around the CG-PCL NFM-coated Ti implant and related in vivo pull-out tests to demonstrate mechanical stability of microgrooved-Ti. - Our research demonstrates: (1) immobilization of ECM proteins (CG and FN) and bone growth factors (BMP2) with PCL NFM is possible, and such immobilization improves the in vitro cell viability of PCL NFM; (2) immobilization of antibacterial nanoparticles (Ag) with PCL NFM is possible, and such immobilization improves the in vitro antibacterial activity of PCL NFM; (3) direct attachment of FN on a dental implant material (Ti-6Al-4V) is possible using tresyl chloride activation method; and (4) microgrooving of a Ti implant followed by coating the microgrooves with CG-PCL NFM significantly improves in vivo mechanical stability and osseointegration.
- Referring to
FIG. 1 , in a preferred embodiment thepresent invention 10 provides coating methods described above to dental implants with the goal of improving the osseointegration of implants. We use a laser pulse to createmicrogrooves 11 at the interspace between twothreads 18 of a dental implant (Di) 12. Laser-inducedmicrogrooves 11 were shown in our research to significantly influence the surface morphology, contact angle, surface roughness, and chemical composition of Ti that can influence the attachment of fibronectin on implants. A set ofcontinuous microgrooves 11 with 50 μm width, 5 μm depth, and 150 μm spacing between grooves are engraved at the root of the threads (˜0.5 mm) on aDi 12 using a laser system (e.g., a Galvo FP fiber marking) to produce a laser-microgrooved Di 13. A rotary stage of the laser system (not shown) is oriented according to the helix angle of the implant threads to produce thelaser microgrooves 11 at theroot 14 of thethreads 18. - Referring to
FIG. 2 , in a preferred embodiment FN is attach on the laser-engravedimplant 12 surface bytresyl chloride method 21, and coats the FN-immobilizedimplant surface 22 with BMP2- and Ag-immobilized PCL NFM as shown 23. Basic terminal hydroxyl groups of apure titanium surface 22 react with tresyl chloride, which allows for further coupling with fibronectin (FN). Previous in vivo studies using a rabbit femur model found that immobilizing fibronectin (FN) onto cylindrical pure titanium implants enhanced bone regeneration around implants. However, pure titanium has limited applications in the biomedical industry due to its inferior mechanical and biological properties, compared to biomedical grade titanium alloys, such as Ti-6Al-4V (the most commonly used titanium alloy in medical devices). We examined whether human plasma FN can be attached to Ti-6Al-4V via the tresyl chloride activation method. Three groups of samples were prepared to test the FN attachment on Ti via the tresyl chloride activation process: (1) control, (2) tresyl chloride-activated Ti (referred to as Tresyl/Ti), and (3) tresyl chloride-activated Ti subsequently coupled with FN (referred to as FN/Ti). To prepare Tresyl/Ti, the top surface of a polished Ti-6Al-4V sample was treated with 2,2,2-Trifluoroethanesulfonyl chloride at 36° C. for 48 hours, then washed with water, water-acetone (50:50), and acetone. Samples were then dried and stored in a desiccator. To prepare FN/Ti, a Tresyl/Ti sample was treated for 24 hours at 37° C. with human plasma fibronectin diluted in phosphate-buffered saline (PBS) solution to a concentration of 0.1 mg/mL. X-ray photoelectron spectroscopy (XPS) analysis was conducted on all samples to determine the chemical state of Ti. The binding energy for each spectrum was calibrated against the C1s peak at 284.8 eV. - Referring to
FIG. 3 , XPS analysis found the presence of an amide group for FN/Ti, which confirms the surface activation by tresyl chloride and then direct coupling of FN with Ti. The N1s peak, derived from the amide bond of immobilized fibronectin, was detected around the binding energy of 400 eV for only FN/Ti samples. Therefore, this study suggested that direct attachment of FN is possible on a tresylated Ti alloy surface. Our proof of concept for the potential application of the treatment protocols on a Di led to the following: an ideal functional coating for a Di must reabsorb with time to allow and encourage new bone formation while maintaining its osteoconductive properties in vivo. - Referring to
FIG. 4 , the present invention provideslaser engraving 41 to support attachment of FN on a dental implant (FIG. 1-12 ) and then coating the implant with BMP2 and Ag NP-immobilized PCL NFM. A laser pulse can be applied on the polished surfaces of Ti to create linear and continuous microgrooves on Ti implants. A laser capable of producing precision microgrooves (FIG. 1-11 ) on at least the flat surface of aTi rod 42 can be used for this purpose. In our research we have used a Galvo FP fiber marking laser equipped with software for engraving a set of microgrooves (10 μm width, 5 μm depth, and 50 μm spacing between grooves) on Ti. The reason for achieving 5 μm-deep microgrooves on Ti is due to the fact that each groove of this size can accommodate at least 18 layers of nanofiber (average fiber diameter ˜300 nanometers). In the present invention, we use 18 layers of PCL NFM because our research shows that the porosity of a PCL NFM membrane comprising 18 layers of fibers is adequate for cells to migrate through the membrane. FN can be attached on laser engraved Ti implants (lgTi), where immobilization of FN with Ti is accomplished by the tresyl chloride method as provided by the present invention. - Referring to
FIG. 5 , aligned unidirectional PCL NFM can be collected using the methods disclosed in U.S. Pat. No. 9,809,906 by the present Applicant and illustrated inFIG. 5 . The laser-grooved surface of lgTi is activated by tresyl chloride and then 18 layers of PCL NFM is deposited along the direction of the thread (clockwise) by rotating thetresylated Di 18 times until the implant collects 18 layers of fibers. The reason for adapting this coating method on a Di surface is due to fact that such a method should be able to maintain nanofibers along the Di/bone interface. FN, FN-Hep-BMP2 and CG-Ag complexes are gently splashed on the PCL coated Di samples to prepare FN-PCL/Di, FN-BMP-PCL/Di and CG-Ag-PCL/Di Di, respectively. All implants are prepared under sterile conditions and kept for 30 minutes in a portable ultraviolet sterilizer before surgery. - Referring to
FIGS. 6a and 6b , in a method validation test we coated a M3×0.5 screw by PCL NFM using the method of the present invention (FIG. 5 ). We torqued the fiber-coated screw in to a pre-drilled hole (2.6 mm) on clear acrylic (FIG. 6b ). We observed homogeneously-distributed fiber along the interface between the screw and the acrylic (FIG. 6b ). - Bone morphogenic proteins (BMPs) play important roles in in osteoblast and chondrocyte differentiation. Research shows that surface functionalization of Ti with BMP2 improves the osteoblast activities of Ti. Among BMP family members, BMP2 is a potent osteoinductive factor that plays key role during bone formation. Fibronectin (FN) is a multifunctional protein most abundantly found in the extracellular matrix (ECM) under dynamic remodeling conditions such as bone healing and development. Research shows that tethering of FN onto Ti effectively enhanced the bone regeneration around implants. Our preliminary studies show that FN-immobilized PCL NFM (referred as FN-PCL) has higher biocompatibility with osteoblast cells in comparison to PCL. FN contains binding domains for many bone growth signaling factors, including BMP2 and transforming growth factor-beta (TGF-β). We have successfully immobilized BMP2 with PCL NFM using FN in our preliminary studies. The effect of BMP2-immobilized PCL NFM coating on the osteogenic functions of Ti is not known and thus it needs to be investigated.
- Prolonged anti-bacterial activities of an implant are possible by tethering anti-bacterial molecules with the implant. Many studies reported that Ag NP inhibits bacterial growth, while retaining/promoting osteoblast viability. Among common antibacterial nanoparticles (Ag, CuO, ZnO), Ag NP shows the minimum toxicity to environmentally relevant test organisms and mammalian cells in vitro and in vivo. Since Ag NP dissolves in CG, it can be immobilized with CG-PCL NFM. Our in vivo and in vitro studies show that CG-PCL NFM coating enhanced biological functions of Ti. This is due to the fact that higher cell functions were created via better cell signaling arising from the cell-cell contact and the cell-NFM components in the case of the CG-PCL NFM-coated Ti samples than non-coated Ti samples. Our preliminary studies showed no antimicrobial activity of Ag NP-immobilized CG-PCL NFM towards Staphylococcus aureus in comparison to PCL NFM. The effect of Ag NP-tethered CG-PCL NFM on the osteogenic and anti-bacterial activities towards other common aerobic bacterial organisms on Ti implant is not known and thus needs to be investigated.
- Fibronectin (FN) contains several active sites, known as the heparin-binding domains, collagen-binding domain, fibrin-binding domain, and cell-binding domain, that serve as platforms for cell anchorage. The goal of this preliminary study was to evaluate the effect of immobilization of collagen and plasma fibronectin with PCL NFM on the cellular functions of PCL NFM. The results (
FIG. 7a andFIG. 7b ) show that the individual immobilization of CG and FN on PCL NFM has no adverse effect on osteoblast cells adhesion and proliferation of PCL NFM, although a significant increase of cell adhesion was observed for FN-PCL-NFM when compared to PCL NFM (p<0.05). A significant improvement of cell adhesion and proliferation was observed for FN-CG-PCL NFM in comparison to PCL NFM (p<0.01). This is due to the fact that higher cell functions were created via better cell signaling arising from the cell-cell contact and the cell-NFM components in the case of FN-CG immobilized PCL NFM compared to PCL NFM. - Direct attachment of FN on a Ti implant surface is possible using a Tresyl Chloride-Activated Method (shown in Section C.5.). Since FN contains a CG binding domain, FN-immobilized Ti can therefore be polymerized into CG-PCL. The effect of the attachment of PCL NFM with Ti using CG and FN on the osteogenic functions of the implant is not known and needs to be investigated.
- Immobilization of Human Bone Morphogenic Protein-2 (BMP2) with PCL NFM Using Fibronectin (FN).
- The PCL NFM can be modified with heparin (Hep) and further immobilized with BMP2. The modified fibers showed the potential to effectively induce osteogenic differentiation of periodontal ligament cells. Since FN contains heparin-binding domains, PCL fibers can be modified with FN-Hep-BMP2 complex. The purpose of this preliminary study was threefold: (1) to immobilize BMP2 on PCL NFM using only FN-BMP2 and FN-Hep-BMP2 complexes, (2) to determine the amount of BMP2 release from the immobilized BMP2-PCL NFM, and (3) to compare the cell viability of BMP2-immobilized PCL NFMs with respect to PCL NFM (control). Immobilized BMP2 was released from the PCL NFMs in a sustained manner for 28 days, although the rates of release of BMP2 from FN-BMP2/PCL and FN-Hep-BMP2/PCL were different. A gradual increase of release of BMP2 for 28 days was observed for FN-Hep-BMP2/PCL samples (
FIG. 8a ). Rapid release of BMP2 for first 4 days, then gradual decline of release of BMP2 with time was observed for FN-BMP2/PCL samples. Cells displayed a well-extended morphology on all the BMP2-treated groups, when they were compared with the control group (8 a).FIG. 8b depicts a representative image showing cell divisions after 48 hours of cell culture on FN-BMP2-PCL samples. In the image, blue color shows the attachment of cells on NFM. There was more than a 52% and 30% increase in the cell viability on FN-Hep-BMP2-PCL samples after culturing the cells for 72 hours compared to control and FN-BMP2-PCL. Both release and cell viability tests suggested an advantage of FN-Hep-BMP2 over FN-BMP2 complex for the immobilization of BMP2 with PCL NFM. FN-Hep-BMP2 immobilized PCL NFM has the potential to induce osteogenic differentiation of osteoblast cells on a Ti implant surface, which is not yet known. The effect of the treatment of Ti with FN by tresyl chloride method and then coating by FN-Hep-BMP2/PCL on the osteogenic functions needs to be investigated. - Attachment of Silver Nanoparticles (Ag NP) with PCL NFM Using CG
- Silver nanoparticles (Ag NP) show promising anti-bacterial properties with biocompatibility and minimal toxicity. Ag NP-loaded collagen was immobilized with polymeric film to inhibit bacterial growth while promoting osteoblast cell viability. The anti-bacterial activities of PCL NFM can be improved by immobilizing Ag NP-loaded CG with PCL NFM. The purpose of this preliminary study was to examine the effect of immobilization of Ag NP-loaded CG on the anti-bacterial properties of PCL NFM. We succeeded in immobilizing Ag-loaded collagen with PCL NFM. The SEM and XRD analysis before and after 2 days of bacterial culture confirmed the presence of Ag with PCL. Our bacterial culture studies showed no sign of colonies growing on Ag-CG-PCL, whereas the presence of bacteria was observed in PCL.
FIG. 9 shows PCL samples after Gram staining: (a) PCL and (b) CG-Ag-PCL. S. aureus that take up the Gram stain were present in PCL, as observed in the image by circular black shapes (pointed by arrows), while CG-Ag-PCL without S. aureus, did not stain and appears with a gray color. One reason for this might arise from an increased carrying capacity of Ag NP-loaded collagen by the nanofiber disc due to its unique surface-to-volume ratio. - In Vivo Evaluation of Coating a Titanium Implant with CG-PCL NFM
- We have invented a method of coating a cylindrical metal implant with NFM that is made with CG-PCL (U.S. Pat. No. 9,809,906). Our invention implements a set of grooves that are created on Ti in a circumferential direction to increase the contact area between the implant and bone. CG-PCL NFM is subsequently coated along the sub-micrometer grooves on the Ti implant using our unique electrospinning process (U.S. Pat. No. 9,359,694). The goal of this research was to evaluate the effect of CG-PCL NFM coating on the mechanical stability and osseointegration of a Ti implant using a rabbit model. Our in vivo pull-out tests demonstrated that mechanical stability of microgrooved-Ti was significantly higher compared to non-grooved Ti. The mechanical stability (quantified by shear strength) of groove-NFM Ti/bone samples were significantly greater compared to other samples (p<0.05). The pull-out strength of groove-NFM-coated Ti was comparable to other functional coating-treated Ti reported in the literature. The types of new bone growth on Ti was different between groove and groove-NFM samples, which was observed from the stained images of histology-sectioned images (
FIG. 10e ). Histomorphometric results showed that the amount of BIC on Ti was higher for groove-NFM (12.18±0.94 mm, n=2) than groove (5.30±4.01 mm, n=2) samples. Due to the poor attachment of Ti with bone, Ti implants came out from their implant sites during histology preparation. Therefore, there was no result for any control sample. Both μCT analyses (FIG. 10e andFIG. 10f ) and blood serum (FIG. 10g ) results confirmed the time-dependent bone growth around the CG-PCL NFM-coated Ti implant and determined that 6 weeks were required for sufficient bone growth around the implant. - Our in vivo pull-out tests demonstrated that mechanical stability of microgrooved-Ti was significantly higher compared to non-grooved Ti (
FIG. 10c ). The mechanical stability (quantified by shear strength) of groove-NFM Ti/bone samples were significantly greater compared to other samples (p<0.05). The pull-out strength of groove-NFM-coated Ti was comparable to other functional coating-treated Ti reported in the literature. The types of new bone growth on Ti was different between groove and groove-NFM samples, which was observed from the stained images of histology-sectioned images (FIG. 10e ). Histomorphometric results showed that the amount of BIC on Ti was higher for groove-NFM (12.18±0.94 mm, n=2) than groove (5.30±4.01 mm, n=2) samples. Due to the poor attachment of Ti with bone, Ti implants came out from their implant sites during histology preparation. Therefore, there was no result for any control sample. Both μCT analyses (FIG. 10e andFIG. 10f ) and blood serum (FIG. 10g ) results confirmed the time-dependent bone growth around the CG-PCL NFM-coated Ti implant and determined that 6 weeks were required for sufficient bone growth around the implant. - Further modifications and alternative embodiments of various aspects of the invention will be apparent to those skilled in the art in view of this description. Accordingly, this description is to be construed as illustrative only and is for the purpose of teaching those skilled in the art the general manner of carrying out the invention. It is to be understood that the forms of the invention shown and described herein are to be taken as examples of embodiments. Elements and materials may be substituted for those illustrated and described herein, parts and processes may be reversed, and certain features of the invention may be utilized independently, all as would be apparent to one skilled in the art after having the benefit of this description of the invention. Changes may be made in the elements described herein without departing from the spirit and scope of the invention as described in the following claims.
Claims (21)
1-9. (canceled)
10. A threaded intraosseous implant, comprising:
a cylindrical device having external threads extending from a root of the device along a helix angle with interspaces located between turns of said threads;
grooved surfaces comprising at least one microgroove at the interspaces between thread turns and oriented according to the helix angle of said threads;
nanofibers coating said grooved surfaces, said nanofibers substantially aligned with the helix angle of said threads,
wherein, said at least one microgroove is adapted to mitigate physiological loading of said nanofibers during insertion of said implant into biological bone.
11. The threaded intraosseous implant according to claim 24 , wherein said at least one microgroove exhibits a capacity to hold 18 layers of nanofibers.
12. The threaded intraosseous implant of claim 25 , wherein said nanofibers are adhered to said microgrooves.
13. The threaded intraosseous implant of claim 26 , further comprising tresyl chloride coupled with fibronectin (FN) coating said grooved surfaces;
14. The threaded intraosseous implant of claim 24 , wherein said intraosseous implant is adapted to attach a prosthesis to said biological bone.
15. The threaded intraosseous implant according to claim 24 , wherein said intraosseous implant is one of a hollow or solid screw device.
16. A threaded intraosseous implant, comprising:
a cylindrical device having external threads extending from a root of the device along a helix angle with interspaces located between turns of said threads;
grooved surfaces comprising at least two microgrooves at the interspaces between thread turns and oriented according to the helix angle of said threads;
nanofibers coating said grooved surfaces, said nanofibers substantially aligned with the helix angle of said threads,
wherein, said at least two microgrooves are adapted to mitigate physiological loading of said nanofibers during insertion of said intraosseous implant into biological bone, and wherein said intraosseous implant is adapted to attach a prosthesis to said biological bone.
17. The threaded intraosseous implant according to claim 30, wherein said at least two microgrooves exhibit a capacity to hold 18 layers of nanofibers where microgroove depth is 5 μm.
18. The threaded intraosseous implant of claim 30, further comprising tresyl chloride coupled with fibronectin (FN) coating said grooved surfaces.
19. The threaded intraosseous implant of claim 30, wherein said nanofibers further comprise a nanofiber matrix (NFM) adhering to said grooved surfaces.
20. The medical intraosseous implant according to claim 30, wherein said intraosseous implant is one of a hollow or solid screw device.
21. A threaded intraosseous implant, comprising:
a threaded cylindrical device and having an external thread extending from a root of the device along a helix angle with interspaces located between turns of the thread;
grooved surfaces comprising of two parallel microgrooves at the interspaces between the thread turns and oriented according to the helix angle of said thread to provide a helix angle of the microgrooves,
tresyl chloride coupled with fibronectin (FN) coating said grooved surfaces;
a nanofiber matrix (NFM) coating said grooved surfaces, said NFM substantially aligned with the helix angle of said microgrooves,
wherein, said NFM is adhered to said grooved surfaces of said intraosseous implant, and
wherein, said microgrooves are adapted to at least mitigate physiological loading of said NFM.
22. The threaded intraosseous implant according to claim 35, wherein said microgrooves exhibit a capacity to hold 18 layers of nanofibers where microgroove depth is at least 5 μm.
23. The medical intraosseous implant according to claim 35, wherein said NFM comprises 18 fiber layers, said layers deposited circumferentially along the helix angle of said microgrooves and shielded from applied loads.
24. The threaded intraosseous implant of claim 35, wherein said microgrooves are engraved to a depth of 5 μm, a width of 50 μm, and a spacing of 50 μm to 150 μm between said grooves at the interspace of said thread.
25. The threaded intraosseous implant of claim 35, further comprising attached collagen loaded with silver nanoparticles (Ag NP) or antimicrobial analogs thereof.
26. The threaded intraosseous implant of claim 35, wherein said NFM comprises at least one of growth factor or antibiotic-modified polycapronlectron (PCL) Electrospun Nanofibers (ENFs), said PCL-ENF combined with at least any of Platelet Derived Growth Factor (PDGF), Bone Morphogenetic Protein 2 (BMP2), PDGF+BMP2, or BMP2 and silver (Ag).
27. The threaded intraosseous implant of claim 35, wherein said intraosseous implant is adapted for insertion in biological bone, and further adapted to attach a prosthesis to said biological bone.
28. The threaded intraosseous implant according to claim 35, wherein said intraosseous implant further comprises Titanium or analogs thereof.
29. The threaded intraosseous implant according to claim 35, wherein said intraosseous implant is one of a hollow or solid screw device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/476,182 US20220000588A1 (en) | 2014-08-18 | 2021-09-15 | High strength intraosseous implants |
Applications Claiming Priority (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462038506P | 2014-08-18 | 2014-08-18 | |
US14/734,147 US10415156B2 (en) | 2014-08-18 | 2015-06-09 | Method and apparatus for controlled alignment and deposition of branched electrospun fiber |
US201662312041P | 2016-03-23 | 2016-03-23 | |
US201662373786P | 2016-08-11 | 2016-08-11 | |
US15/467,652 US9809906B2 (en) | 2014-08-18 | 2017-03-23 | Method and apparatus to coat a metal implant with electrospun nanofiber matrix |
US15/674,309 US9974883B2 (en) | 2016-08-11 | 2017-08-10 | Method and apparatus to control the heterogeneous flow of bone cement and improve osseointegration of cemented implant |
US15/791,571 US10206780B2 (en) | 2014-08-18 | 2017-10-24 | Method and apparatus to coat a metal implant with electrospun nanofiber matrix |
US201862634993P | 2018-02-26 | 2018-02-26 | |
US15/976,615 US10286103B2 (en) | 2016-08-11 | 2018-05-10 | Method and apparatus to control the heterogeneous flow of bone cement and improve osseointegration of cemented implant |
US16/248,122 US10932910B2 (en) | 2014-08-18 | 2019-01-15 | Nanofiber coating to improve biological and mechanical performance of joint prosthesis |
US16/286,005 US11058521B2 (en) | 2014-08-18 | 2019-02-26 | Method and apparatus for improving osseointegration, functional load, and overall strength of intraosseous implants |
US17/374,700 US20210338383A1 (en) | 2014-08-18 | 2021-07-13 | High strength intraosseous implants |
US17/476,182 US20220000588A1 (en) | 2014-08-18 | 2021-09-15 | High strength intraosseous implants |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US17/374,700 Continuation US20210338383A1 (en) | 2014-08-18 | 2021-07-13 | High strength intraosseous implants |
Publications (1)
Publication Number | Publication Date |
---|---|
US20220000588A1 true US20220000588A1 (en) | 2022-01-06 |
Family
ID=67684066
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/286,005 Active 2035-07-01 US11058521B2 (en) | 2014-08-18 | 2019-02-26 | Method and apparatus for improving osseointegration, functional load, and overall strength of intraosseous implants |
US17/374,700 Abandoned US20210338383A1 (en) | 2014-08-18 | 2021-07-13 | High strength intraosseous implants |
US17/476,182 Abandoned US20220000588A1 (en) | 2014-08-18 | 2021-09-15 | High strength intraosseous implants |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/286,005 Active 2035-07-01 US11058521B2 (en) | 2014-08-18 | 2019-02-26 | Method and apparatus for improving osseointegration, functional load, and overall strength of intraosseous implants |
US17/374,700 Abandoned US20210338383A1 (en) | 2014-08-18 | 2021-07-13 | High strength intraosseous implants |
Country Status (1)
Country | Link |
---|---|
US (3) | US11058521B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10932910B2 (en) * | 2014-08-18 | 2021-03-02 | University of Central Oklahoma | Nanofiber coating to improve biological and mechanical performance of joint prosthesis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098442A1 (en) * | 2003-05-03 | 2004-11-18 | Wolfgang Dinkelacker | Bone implant that can be screwed in |
DE102004017344A1 (en) * | 2004-04-06 | 2005-11-03 | Schröder, Ralf, Dr. | Dental implant, comprising threaded segments positioned between windings of thread with higher flanks |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US692631A (en) | 1899-10-06 | 1902-02-04 | Charles S Farquhar | Apparatus for electrically dispersing fluids. |
GB364780A (en) | 1929-12-07 | 1932-01-14 | Anton Formhals | Improvements in or relating to processes and apparatus for the production of artificial filaments |
US2109333A (en) | 1936-03-04 | 1938-02-22 | Richard Schreiber Gastell | Artificial fiber construction |
US2123992A (en) | 1936-07-01 | 1938-07-19 | Richard Schreiber Gastell | Method and apparatus for the production of fibers |
US2187306A (en) | 1937-07-28 | 1940-01-16 | Richard Schreiber Gastell | Artificial thread and method of producing same |
US2349950A (en) | 1937-08-18 | 1944-05-30 | Formhals Anton | Method and apparatus for spinning |
US4536894A (en) | 1983-08-04 | 1985-08-27 | Galante Jorge O | Hip prosthesis with flared porous bony ingrowth pads |
US4655769A (en) | 1984-10-24 | 1987-04-07 | Zachariades Anagnostis E | Ultra-high-molecular-weight polyethylene products including vascular prosthesis devices and methods relating thereto and employing pseudo-gel states |
US4636219A (en) | 1985-12-05 | 1987-01-13 | Techmedica, Inc. | Prosthesis device fabrication |
US5013324A (en) | 1987-08-24 | 1991-05-07 | Zimmer, Inc. | Prosthetic implant with wrapped porous surface |
US5507833A (en) | 1992-02-10 | 1996-04-16 | Kim-Med, Inc. | Hip replacement system and method for implanting the same |
US5370698A (en) | 1992-04-16 | 1994-12-06 | Clemson University | Isoelastic implants with improved anchorage means |
US6419491B1 (en) * | 1993-11-02 | 2002-07-16 | Bio-Lok International, Inc. | Dental implant system with repeating microgeometric surface patterns |
US5504300A (en) | 1994-04-18 | 1996-04-02 | Zimmer, Inc. | Orthopaedic implant and method of making same |
US6066176A (en) | 1996-07-11 | 2000-05-23 | Oshida; Yoshiki | Orthopedic implant system |
US6106913A (en) | 1997-10-10 | 2000-08-22 | Quantum Group, Inc | Fibrous structures containing nanofibrils and other textile fibers |
EP1193047A4 (en) | 1999-05-12 | 2004-10-27 | Kaneka Corp | Multi-layer endless belt, medium conveying belt consisting of it, and production methods and forming devices therefor |
US6355699B1 (en) | 1999-06-30 | 2002-03-12 | Ethicon, Inc. | Process for manufacturing biomedical foams |
US6753454B1 (en) | 1999-10-08 | 2004-06-22 | The University Of Akron | Electrospun fibers and an apparatus therefor |
US6743273B2 (en) | 2000-09-05 | 2004-06-01 | Donaldson Company, Inc. | Polymer, polymer microfiber, polymer nanofiber and applications including filter structures |
US7244272B2 (en) | 2000-12-19 | 2007-07-17 | Nicast Ltd. | Vascular prosthesis and method for production thereof |
US6821479B1 (en) | 2001-06-12 | 2004-11-23 | The University Of Akron | Preservation of biological materials using fiber-forming techniques |
US20030113478A1 (en) | 2001-12-12 | 2003-06-19 | Dang Mai Huong | Surface coating method and coated device |
KR100491228B1 (en) | 2003-02-24 | 2005-05-24 | 김학용 | A process of preparing continuous filament composed of nano fiber |
US20050119758A1 (en) * | 2003-07-30 | 2005-06-02 | Bio-Lok International Inc. | Surgical implant for promotion of osseo-integration |
CA2536041A1 (en) | 2003-11-10 | 2005-05-26 | Angiotech International Ag | Medical implants and fibrosis-inducing agents |
US20090189319A1 (en) | 2004-02-02 | 2009-07-30 | Kim Hak-Yong | Process of preparing continuous filament composed of nanofibers |
WO2005096744A2 (en) | 2004-03-31 | 2005-10-20 | The Regents Of The University Of California | Oriented polymer fibers and methods for fabricating thereof |
US7762801B2 (en) | 2004-04-08 | 2010-07-27 | Research Triangle Institute | Electrospray/electrospinning apparatus and method |
EP1761283A2 (en) | 2004-06-07 | 2007-03-14 | California Institute Of Technology | Biodegradable drug-polymer delivery system |
JP5031559B2 (en) | 2004-06-17 | 2012-09-19 | コリア リサーチ インスティチュート オブ ケミカル テクノロジー | Filament bundle-like long fibers and method for producing the same |
WO2007015710A2 (en) | 2004-11-09 | 2007-02-08 | Board Of Regents, The University Of Texas System | The fabrication and application of nanofiber ribbons and sheets and twisted and non-twisted nanofiber yarns |
DE602004025992D1 (en) | 2004-11-12 | 2010-04-22 | Hak-Yong Kim | METHOD FOR THE PRODUCTION OF ENDLESS FILAMENT FROM NANO FIBERS |
US10328032B2 (en) | 2005-03-04 | 2019-06-25 | Biosurfaces, Inc. | Nanofibrous materials as drug, protein, or genetic release vehicles |
CN100334268C (en) | 2005-03-25 | 2007-08-29 | 东南大学 | Method for preparing nano fiber endless tow |
US7575707B2 (en) | 2005-03-29 | 2009-08-18 | University Of Washington | Electrospinning of fine hollow fibers |
US7799262B1 (en) | 2005-05-02 | 2010-09-21 | Industrial Cooperation Foundation Chonbuk National University | Method of manufacturing a continuous filament by electrospinning |
KR100621428B1 (en) | 2005-06-17 | 2006-09-07 | 전북대학교산학협력단 | Method of manufacturing a continuous filament by electrospinning and continuous filament manufactured thereby |
CA2629405C (en) | 2005-09-09 | 2016-06-21 | Duke University | Tissue engineering methods and compositions |
CN100427652C (en) | 2005-11-11 | 2008-10-22 | 东南大学 | Composite nano fiber endless tow preparing apparatus and its preparing method |
CN100390332C (en) | 2005-11-25 | 2008-05-28 | 清华大学 | Electric device and method for spinning generation and collection |
US20070275458A1 (en) | 2005-12-09 | 2007-11-29 | The Research Foundation Of State University Of New York | Three dimensional-BIO-mimicking active scaffolds |
EP1974015A4 (en) | 2006-01-27 | 2012-07-04 | Univ California | Biomimetic scaffolds |
CZ299549B6 (en) | 2006-09-04 | 2008-08-27 | Elmarco, S. R. O. | Rotary spinning electrode |
WO2008111960A2 (en) | 2006-09-29 | 2008-09-18 | University Of Akron | Metal oxide fibers and nanofibers, method for making same, and uses thereof |
WO2008051228A1 (en) | 2006-10-27 | 2008-05-02 | Dai, Sasha | Skin substitutes, preparation methods and uses thereof |
US20080112998A1 (en) | 2006-11-14 | 2008-05-15 | Hongjun Wang | Innovative bottom-up cell assembly approach to three-dimensional tissue formation using nano-or micro-fibers |
US8728170B1 (en) | 2006-12-28 | 2014-05-20 | Boston Scientific Scimed, Inc. | Bioerodible nano-fibrous and nano-porous conductive composites |
US8753391B2 (en) | 2007-02-12 | 2014-06-17 | The Trustees Of Columbia University In The City Of New York | Fully synthetic implantable multi-phased scaffold |
JP2010522620A (en) | 2007-03-26 | 2010-07-08 | ユニヴァーシティ オブ コネチカット | Electrospun apatite / polymer nanocomposite skeleton |
US7828539B1 (en) | 2007-03-26 | 2010-11-09 | Clemson University | Fabrication of three dimensional aligned nanofiber array |
EP2155935B1 (en) | 2007-04-11 | 2012-01-25 | National University of Singapore | Fibers for decontamination of chemical and biological agents |
WO2008151117A1 (en) | 2007-06-01 | 2008-12-11 | United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Method and system for aligning fibers during electrospinning |
US20100028387A1 (en) | 2007-06-12 | 2010-02-04 | Ganesan Balasundaram | Biocompatible Coated Nanostructured Titanium Surfaces |
JP2010532435A (en) | 2007-06-29 | 2010-10-07 | スリーエム イノベイティブ プロパティズ カンパニー | Indicator fiber |
ATE502140T1 (en) | 2007-10-02 | 2011-04-15 | Stem Cell Technology Company | DEVICE AND METHOD FOR ELECTROSPINNING 2D OR 3D STRUCTURES OF MICRO OR NANOFIBER MATERIALS |
WO2009101472A2 (en) | 2007-11-02 | 2009-08-20 | National University Of Singapore | Stent coated with aligned nanofiber by electrospinning |
US20090118813A1 (en) | 2007-11-02 | 2009-05-07 | Torsten Scheuermann | Nano-patterned implant surfaces |
WO2009099570A2 (en) | 2008-02-01 | 2009-08-13 | Wake Forest University Health Sciences | Aligned scaffolding system for skeletal muscle regeneration |
US20090294733A1 (en) | 2008-05-29 | 2009-12-03 | Kelly Dean Branham | Process for improved electrospinning using a conductive web |
US9023376B2 (en) | 2008-06-27 | 2015-05-05 | The University Of Akron | Nanofiber-reinforced composition for application to surgical wounds |
US9029149B2 (en) | 2008-07-31 | 2015-05-12 | Carnegie Mellon University | Methods, apparatus, and systems for fabrication of polymeric nano- and micro-fibers in aligned configurations |
WO2010054121A2 (en) | 2008-11-07 | 2010-05-14 | Specialized Vascular Technologies, Inc. | Extracellular matrix modulating coatings for medical devices |
US9452049B2 (en) | 2008-11-24 | 2016-09-27 | Georgia Tech Research Corporation | Systems and methods to affect anatomical structures |
US8470236B2 (en) | 2008-11-25 | 2013-06-25 | E I Du Pont De Nemours And Company | Process of making a non-woven web |
US8475531B1 (en) | 2009-04-21 | 2013-07-02 | Scott A. Maxson | Anchored multi-phasic osteochondral construct |
US20100310623A1 (en) | 2009-06-05 | 2010-12-09 | Laurencin Cato T | Synergetic functionalized spiral-in-tubular bone scaffolds |
US20100327494A1 (en) | 2009-06-22 | 2010-12-30 | University Of South Carolina | Electrospun Fibrous Three-Dimensional Scaffolds with Well-Defined Pore Geometry |
US10413391B2 (en) | 2010-04-01 | 2019-09-17 | Rensselaer Polytechnic Institute | Three-dimensinoal scaffolds, methods for fabricating the same, and methods of treating a peripheral nerve or spinal cord injury |
US9428849B2 (en) | 2010-06-21 | 2016-08-30 | University Of South Florida | Polypeptide electrospun nanofibrils of defined composition |
WO2012078472A2 (en) | 2010-12-05 | 2012-06-14 | Nanonerve, Inc. | Fibrous polymer scaffolds having diametrically patterned polymer fibers |
US20130030452A1 (en) | 2011-07-27 | 2013-01-31 | Health Corporation - Rambam | Devices for surgical applications |
CA2792081C (en) | 2011-10-11 | 2020-10-27 | Bond University Ltd | Layered compositions comprising 3d nanofibre webbing for tissue repair |
US9618501B2 (en) | 2012-02-23 | 2017-04-11 | University Of South Florida | Three-dimensional fibrous scaffolds for cell culture |
US9925301B2 (en) | 2012-04-06 | 2018-03-27 | Trustees Of Tufts College | Methods of producing and using silk microfibers |
US9180223B2 (en) | 2012-05-10 | 2015-11-10 | The Trustees Of The Stevens Institute Of Technology | Biphasic osteochondral scaffold for reconstruction of articular cartilage |
WO2014063013A1 (en) | 2012-10-18 | 2014-04-24 | The University Of Akron | Apparatus and method for electrospinning a nanofiber coating on surfaces of poorly conductive three-dimensional objects |
US20150290354A1 (en) | 2012-10-22 | 2015-10-15 | North Carolina State University | Nonwoven fiber materials |
WO2014066884A1 (en) | 2012-10-26 | 2014-05-01 | Tufts University | Silk-based fabrication techniques to prepare high strength calcium phosphate ceramic scaffolds |
US20140205971A1 (en) | 2013-01-18 | 2014-07-24 | The Trustees Of The Stevens Institute Of Technology | Modification of root form dental implants for accelerated tissue regeneration |
US8889178B2 (en) | 2013-03-14 | 2014-11-18 | Prosidyan, Inc | Bioactive porous bone graft compositions in synthetic containment |
WO2014149279A1 (en) | 2013-03-15 | 2014-09-25 | The George Washington University, A Congressionally Chartered Not-For-Profit Corporation | Biomimetic biphasic 3d nanocomposite scaffold for osteochondral regeneration |
WO2014188420A1 (en) | 2013-05-20 | 2014-11-27 | Ramot At Tel-Aviv University Ltd. | Metal-coated scaffolds for tissue engineering |
US9327448B2 (en) | 2013-08-02 | 2016-05-03 | Northwestern University | Methods for fabricating three-dimensional metallic objects via additive manufacturing using metal oxide pastes |
JP2015051240A (en) * | 2013-09-09 | 2015-03-19 | 株式会社ナントー | Implant body, implant, and method of manufacturing implant body |
WO2015048224A1 (en) | 2013-09-25 | 2015-04-02 | Johnson Jed K | Fiber scaffolds for use creating implantable structures |
US9566296B2 (en) | 2013-11-08 | 2017-02-14 | Warsaw Orthopedic, Inc. | Multi-layered anti-adhesion device |
PL3083233T3 (en) | 2013-12-17 | 2022-02-07 | Nurami Medical Ltd | A tissue substitute multilayer matrix and uses thereof |
US11739452B2 (en) | 2014-01-30 | 2023-08-29 | Poly-Med, Inc. | Time-dependent synthetic biological barrier material |
CN103893828B (en) | 2014-02-28 | 2016-01-20 | 广西医科大学 | A kind of method improving calcium phosphate bone cement toughness |
EP3122558A4 (en) | 2014-03-24 | 2017-12-20 | The Australian National University | Film |
WO2015157647A2 (en) | 2014-04-10 | 2015-10-15 | Rutgers, The State University Of New Jersey | Guiding stem cell differentiation using graphene-nanofiber hybrid scaffolds |
WO2015168332A2 (en) * | 2014-04-30 | 2015-11-05 | Osseodyne Surgical Solutions, Llc | Osseointegrative surgical implant |
US10420861B2 (en) | 2014-06-27 | 2019-09-24 | St1 Co., Ltd. | Nanofiber mats, method of manufacturing the nanofiber mats, and applications to cell culture and nanofibrous membrane for guided bone regeneration |
US10415156B2 (en) | 2014-08-18 | 2019-09-17 | University of Central Oklahoma | Method and apparatus for controlled alignment and deposition of branched electrospun fiber |
US9809906B2 (en) | 2014-08-18 | 2017-11-07 | University of Central Oklahoma | Method and apparatus to coat a metal implant with electrospun nanofiber matrix |
US9359694B2 (en) | 2014-08-18 | 2016-06-07 | University of Central Oklahoma | Method and apparatus for controlled alignment and deposition of branched electrospun fiber |
CN104906637B (en) | 2015-05-15 | 2018-01-12 | 武汉大学 | Porous polymethyl methacrylate base compound rest bone grafting material for carrying medicine of a kind of injectable and preparation method thereof |
WO2016203409A1 (en) | 2015-06-15 | 2016-12-22 | University Of New South Wales | Engineered materials and methods of forming |
US10064736B2 (en) | 2015-06-25 | 2018-09-04 | University of Central Oklahoma | Engineered intervertebral disc (IVD) for degenerated disc disease |
BR112018000399A2 (en) | 2015-07-07 | 2018-09-11 | Nat Univ Singapore | method for preparing a polymeric product, polymeric product, polymeric cell or tissue culture product and polymeric coating solution |
WO2018112203A1 (en) | 2016-12-14 | 2018-06-21 | eLum Technologies, Inc. | Electrospun stents, flow diverters, and occlusion devices and methods of making the same |
WO2018144858A1 (en) | 2017-02-02 | 2018-08-09 | Nanofiber Solutions, Inc. | Methods of improving bone-soft tissue healing using electrospun fibers |
US10610353B2 (en) | 2017-02-03 | 2020-04-07 | Mayo Foundation For Medical Education And Research | Methods for making nanofibrous coverings for implantable medical devices |
-
2019
- 2019-02-26 US US16/286,005 patent/US11058521B2/en active Active
-
2021
- 2021-07-13 US US17/374,700 patent/US20210338383A1/en not_active Abandoned
- 2021-09-15 US US17/476,182 patent/US20220000588A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004098442A1 (en) * | 2003-05-03 | 2004-11-18 | Wolfgang Dinkelacker | Bone implant that can be screwed in |
DE102004017344A1 (en) * | 2004-04-06 | 2005-11-03 | Schröder, Ralf, Dr. | Dental implant, comprising threaded segments positioned between windings of thread with higher flanks |
Also Published As
Publication number | Publication date |
---|---|
US20200352683A9 (en) | 2020-11-12 |
US20190262105A1 (en) | 2019-08-29 |
US11058521B2 (en) | 2021-07-13 |
US20210338383A1 (en) | 2021-11-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Guo et al. | Orchestrating soft tissue integration at the transmucosal region of titanium implants | |
Raut et al. | Biocompatibility of biomaterials for tissue regeneration or replacement | |
Xiao et al. | Bio-functionalization of biomedical metals | |
Parnia et al. | Overview of nanoparticle coating of dental implants for enhanced osseointegration and antimicrobial purposes | |
Ahn et al. | Modification of titanium implant and titanium dioxide for bone tissue engineering | |
Sharma et al. | Silk fibroin nanoparticles support in vitro sustained antibiotic release and osteogenesis on titanium surface | |
von Wilmowsky et al. | Implants in bone: Part I. A current overview about tissue response, surface modifications and future perspectives | |
Buser et al. | Enhanced bone apposition to a chemically modified SLA titanium surface | |
Sabino et al. | Tanfloc/heparin polyelectrolyte multilayers improve osteogenic differentiation of adipose-derived stem cells on titania nanotube surfaces | |
Schliephake et al. | Chemical and biological functionalization of titanium for dental implants | |
Park et al. | Graphene as an enabling strategy for dental implant and tissue regeneration | |
Kummer et al. | Biological applications of anodized TiO2 nanostructures: a review from orthopedic to stent applications | |
Al-Zubaidi et al. | Improvements in clinical durability from functional biomimetic metallic dental implants | |
Nikolova et al. | Advances in multifunctional bioactive coatings for metallic bone implants | |
Chun et al. | The role of nanomedicine in growing tissues | |
Pang et al. | Nanostructured coating of non-crystalline tantalum pentoxide on polyetheretherketone enhances RBMS cells/HGE cells adhesion | |
Ebrahimi | Bone grafting substitutes in dentistry: general criteria for proper selection and successful application | |
US20220000588A1 (en) | High strength intraosseous implants | |
Gulati et al. | Craniofacial therapy: advanced local therapies from nano-engineered titanium implants to treat craniofacial conditions | |
Heydariyan et al. | A comprehensive review: Different approaches for encountering of bacterial infection of dental implants and improving their properties | |
Liu et al. | Mussel-inspired organic–inorganic implant coating based on a layer-by-layer method for anti-infection and osteogenesis | |
WSZCZEPY | Recent trends in surface modification of the titanium biomaterials used for endoosseus dental implants | |
Souza et al. | Nanostructured biomaterials for cranio-maxillofacial and oral applications | |
CN101653384B (en) | Dental implant of surface nano-structure and manufacturing method thereof | |
Mutreja et al. | Cell responses to titanium and titanium alloys |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: UNIVERSITY OF CENTRAL OKLAHOMA, OKLAHOMA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:TAPALTSYAN, VAGAN;KHANDAKER, MORSHED;RIAHINEZHAD, SHAHRAM;AND OTHERS;SIGNING DATES FROM 20170629 TO 20191030;REEL/FRAME:057493/0634 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |